A Study to Evaluate the Safety and Efficacy of Staged Bilateral Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for the Treatment of Essential Tremor
A legfontosabb adatok
- Ki végzi
- Chinese PLA General Hospital
- Hol
- Beijing (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Csak meghívásos
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2024. szept. 26.
- Tervezett befejezés
- 2026. nov. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- ExAblate
- A regiszteradat frissítve
- 2024. november 6.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with essential tremor who already had a focused ultrasound (Exablate) treatment on one side of the brain. They will now be treated on the other side.
- Életkor
- 22 years or older
- Nem
- Men and women
- A betegség stádiuma
- Essential tremor confirmed by a movement disorder specialist that did not respond to medicines. Tremor scores (CRST Part A and Part C) must be 2 or above.
- Korábbi kezelés
- At least two tremor medicines tried, one of them propranolol or primidone. An Exablate procedure at least 9 months before joining. No deep brain stimulation or earlier ablation of the basal ganglia or thalamus.
- Biomarker vagy leletérték
- Skull Density Ratio of at least 0.40 (±0.05) at screening.
A részvétel fő kizáró okai
- Lasting nerve problems or weakness after the first Exablate procedure
- Swallowing problems, speech problems, or a MoCA memory test score below 22
- Pregnancy or breastfeeding
- Unstable heart disease, bleeding problems, or use of blood thinners
- Stroke or other blood vessel disease of the brain, a brain tumor, or implants in the skull or brain
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- Men and women age 22 years or older
- Subject is able and willing to give consent and able to attend all study visits
- Subject is diagnosed with Essential Tremor as confirmed by a movement disorder specialist
- Subject's tremor is refractory to adequate trials of at least two medications, one of which being a first line therapy of either propranolol or primidone. An adequate medication trial is defined as a therapeutic dose of each medication or the development of side effects as the medication dose is titrated
- Subject is diagnosed with medication-refractory Essential Tremor
- A subject who underwent an Exablate index procedure in a clinical trial or in a commercial setting at least 9 months prior to enrolling in this trial
- Subject has a baseline CRST Part A score of 2 or above for postural or intention tremor severity in the upper extremity for the contralateral tremor side while on stable medication
- Subject is able to communicate sensations during the Exablate thalamotomy procedure
- Subject has a baseline CRST Part C score of 2 or above in any one of the items (speaking, eating, drinking, hygiene, dressing, writing, working, and social activities)
Ki nem vehet részt
- Subject receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of Exablate procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of Exablate procedure
- Subject had deep brain stimulation or a prior stereotactic ablation of the basal ganglia or thalamus
- Subjects who have been administered botulinum toxins into the arm, neck, or face for 5 months prior to Baseline
- Subject is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator
- Subject with unstable cardiac status including:; Unstable angina pectoris on medication; documented myocardial infarction within six months of enrollment; Unstable or worsening congestive heart failure; History of a hemodynamically unstable cardiac arrhythmia; Cardiac pacemaker; Severe hypertension (diastolic BP > 100 on medication)
- Subject has history of abnormal systemic or intracranial bleeding, hemorrhage, or coagulopathy
- Subject with cerebrovascular disease, including but not limited to, intracranial aneurysms, dural arteriovenous malformations (AVM), stroke, intracranial atherosclerotic disease, dural arteriovenous fistulas (AVF)
- Subject with active or suspected acute or chronic uncontrolled infection
- More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp
- Subject has abnormal coagulation profile: (PLT < 100,000/μl), PT (>14 sec) or PTT (>36 sec), and INR > 1.3
- Subject experienced any non-transient neurological event or worsening following the Exablate index procedure
- Subject has physical subscale score ≥ 16.5 on the Dysphagia Handicap Index or has been diagnosed with dysphagia
- Subject has score <22 on the Montreal Cognitive Assessment (MoCA)
- Subject has any non-transient hemiparesis as determined by physical examination
- Subject with clinically significant abnormal speech function as determined by a speech pathologist
- Subject of childbearing potential is pregnant or breastfeeding
- Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse
- Subject with an intracranial tumor
- Patients with implanted objects in the skull or the brain
- Subject has an overall Skull Density Ratio of less than 0.40 (±0.05) as calculated at screening
- Subject is unable or willing to tolerate the required prolonged stationary supine position during Exablate procedure (approximately 2-3 hours)
- Subject is currently participating in another clinical investigation with an active treatment arm
- Subject is unable to communicate with the investigator and staff
Helyszínek itt: Kína
- Chinese PLA General HospitalBeijing, KínaCsak meghívásos
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objective of this prospective, single-arm, open-label study is to asses the safety and efficacy of the staged bilateral thalamotomy using transcranial magnetic resonance guided focused ultrasound system ExAblate 4000, InSightec Ltd.
A vizsgálat csoportja
- ExAblate TreatmentA vizsgált kezelés
Participants will undergo a thalamotomy contralateral to their previous treatment with MRgFUS
Kezelés: ExAblate
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2024. november 6.